These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 37199059)
1. Ex vivo factor VIII-modified proliferating human hepatocytes therapy for haemophilia A. Zhang K; Wu N; Cen J; Li J; Wang Z; Xia Q; Hui L Cell Prolif; 2023 May; 56(5):e13467. PubMed ID: 37199059 [TBL] [Abstract][Full Text] [Related]
2. Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A. Gong J; Chung TH; Zheng J; Zheng H; Chang LJ J Biol Chem; 2021 Dec; 297(6):101397. PubMed ID: 34774524 [TBL] [Abstract][Full Text] [Related]
3. Functional Proliferating Human Hepatocytes: In Vitro Hepatocyte Model for Drug Metabolism, Excretion, and Toxicity. Qiao S; Feng S; Wu Z; He T; Ma C; Peng Z; Tian E; Pan G Drug Metab Dispos; 2021 Apr; 49(4):305-313. PubMed ID: 33526515 [TBL] [Abstract][Full Text] [Related]
4. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A. Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169 [TBL] [Abstract][Full Text] [Related]
5. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327 [TBL] [Abstract][Full Text] [Related]
6. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271 [TBL] [Abstract][Full Text] [Related]
7. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene. Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885 [TBL] [Abstract][Full Text] [Related]
8. Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates. Milani M; Canepari C; Liu T; Biffi M; Russo F; Plati T; Curto R; Patarroyo-White S; Drager D; Visigalli I; Brombin C; Albertini P; Follenzi A; Ayuso E; Mueller C; Annoni A; Naldini L; Cantore A Nat Commun; 2022 May; 13(1):2454. PubMed ID: 35508619 [TBL] [Abstract][Full Text] [Related]
9. Efficient adenoviral vector transduction and expression of functional human factor VIII in cultured primary human hepatocytes. Andrews JL; Weaver L; Kaleko M; Connelly S Haemophilia; 1999 May; 5(3):160-8. PubMed ID: 10444282 [TBL] [Abstract][Full Text] [Related]
10. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse. Li YJ; Chen C; Zeng LY; Cao J; Xu KL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177 [TBL] [Abstract][Full Text] [Related]
11. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A. Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313 [TBL] [Abstract][Full Text] [Related]
12. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Neumeyer J; Lin RZ; Wang K; Hong X; Hua T; Croteau SE; Neufeld EJ; Melero-Martin JM Blood Adv; 2019 Dec; 3(24):4166-4176. PubMed ID: 31851760 [TBL] [Abstract][Full Text] [Related]
13. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Kootstra NA; Matsumura R; Verma IM Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905 [TBL] [Abstract][Full Text] [Related]
14. Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter. Picanço V; Heinz S; Bott D; Behrmann M; Covas DT; Seifried E; Tonn T Cytotherapy; 2007; 9(8):785-94. PubMed ID: 17917890 [TBL] [Abstract][Full Text] [Related]
15. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Stein CS; Kang Y; Sauter SL; Townsend K; Staber P; Derksen TA; Martins I; Qian J; Davidson BL; McCray PB Mol Ther; 2001 Jun; 3(6):850-6. PubMed ID: 11407898 [TBL] [Abstract][Full Text] [Related]
16. Current status of haemophilia gene therapy. High KH; Nathwani A; Spencer T; Lillicrap D Haemophilia; 2014 May; 20 Suppl 4():43-9. PubMed ID: 24762274 [TBL] [Abstract][Full Text] [Related]
17. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221 [TBL] [Abstract][Full Text] [Related]
18. Haemophilia A gene therapy. Connelly S; Kaleko M Haemophilia; 1998 Jul; 4(4):380-8. PubMed ID: 9873758 [TBL] [Abstract][Full Text] [Related]
19. Identification of deep intronic variants in 15 haemophilia A patients by next generation sequencing of the whole factor VIII gene. Bach JE; Wolf B; Oldenburg J; Müller CR; Rost S Thromb Haemost; 2015 Oct; 114(4):757-67. PubMed ID: 25948085 [TBL] [Abstract][Full Text] [Related]
20. Haemophilia gene therapy: From trailblazer to gamechanger. Evens H; Chuah MK; VandenDriessche T Haemophilia; 2018 May; 24 Suppl 6():50-59. PubMed ID: 29878653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]